Results 11 to 20 of about 170,356 (264)
The Role of Liquid Biopsy Analytes in Diagnosis, Treatment and Prognosis of Colorectal Cancer
Frontiers in Endocrinology, 2022 Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive tract worldwide and is a serious threat to human life and health. CRC occurs and develops in a multi-step, multi-stage, and multi-gene process, in which abnormal gene ...
JinHua He +8 more
doaj +1 more source
Monitor tumor burden with circulating tumor DNA [PDF]
Cancer Biology & Therapy, 2013 There is a need to identify better biomarkers to monitor diseases and/or assess therapeutic responses. For those with cancer, one can identify DNA fragments that contain somatic mutations originating in the tumor DNA in plasma or serum. There have been several early studies suggesting that advances in sequencing technologies will allow identification ...
William D, Figg, Jim, Reid
openaire +2 more sources
Tumor Biology, 2020 Detection of circulating tumor DNA is a new noninvasive technique with potential roles in diagnostic, follow-up, and prognostic evaluation of patients with many types of solid tumors.
Mariana Cartaxo Alves +8 more
doaj +1 more source
Circulating Tumor DNA in Oncology [PDF]
Processes, 2021 When somatic cells in the human body undergo apoptosis or necrosis, the released DNA enters the bloodstream. This type of DNA is called cell-free DNA (cfDNA). In patients with cancer, DNA released from tumor cells is called circulating tumor DNA (ctDNA), which carries genetic alterations specific to tumor cells.
Saeko Sakaeda, Yoichi Naito
openaire +1 more source
Circulating tumor DNA in Hodgkin lymphoma
Annals of Hematology, 2022 Abstract Somatic mutations of genes involved in NF-κB, PI3K/AKT, NOTCH, and JAK/STAT signaling pathways play an important role in the pathogenesis of Hodgkin lymphoma (HL). HL tumor cells form only about 5% of the tumor mass; however, it was shown that HL tumor-derived DNA could be detected in the bloodstream.
Maria Maco +6 more
openaire +2 more sources
ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
Computational and Structural Biotechnology Journal, 2018 We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview
Martin H.D. Neumann +3 more
doaj +1 more source
Clinical correlates of circulating cell-free DNA tumor fraction.
PLoS ONE, 2021 BackgroundOncology applications of cell-free DNA analysis are often limited by the amount of circulating tumor DNA and the fraction of cell-free DNA derived from tumor cells in a blood sample.
Joerg Bredno +4 more
doaj +1 more source
Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis
The International Journal of Biological Markers, 2018 Purpose: Bone metastases from non-small cell lung cancer (NSCLC) are common, and current prognostic stratification methods are challenging to predict outcomes.
Jiguang Jia +3 more
doaj +1 more source
The importance of circulating tumor products as „liquid biopsies” in colorectal cancer
Journal of Mind and Medical Sciences, 2018 Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Alina Miscoci +6 more
doaj +1 more source
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA [PDF]
Cancer Discovery, 2014 Abstract The ability to study nonhematologic cancers through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven both by major technologic advances, including the isolation of intact cancer cells and the analysis of cancer cell–derived DNA from blood samples ...
Daniel A, Haber, Victor E, Velculescu
openaire +2 more sources